Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab + Phototherapy in Progressive Vitiligo
NCT05917561Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in nonsegmental vitiligo (NSV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Dec 2023; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT05917561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917561.